Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

根据诺和诺德官网管线资料，该公司拟开发这款GIP/GLP-1受体激动剂用于2型糖尿病和减重。根据ClinicalTrials官网，诺和诺德此前已经在美国、日本、澳大利亚、韩国等地已经启动了NNC0519-0130注射液的多项1期和2期临床研究，计划评 ...

根据诺和诺德官网管线资料，该公司拟开发这款GIP/GLP-1受体激动剂用于2型糖尿病和减重。根据ClinicalTrials官网，诺和诺德此前已经在美国、日本、澳大利亚、韩国等地已经启动了NNC0519-0130注射液的多项1期和2期临床研究，计划评估NN0519-0130针对健康人群和2型糖尿病、肥胖人群的药代动力学、安全性和有效性。

拉斯克奖颁奖语提到，全球有近9亿成年人患有肥胖症。体重过重是多种危及生命的疾病的根源。肥胖通常被视为意志力的失败，但对许多人来说，节食和锻炼并不能治愈肥胖问题。从历史上看，制造安全有效的减肥药物的尝试都失败了。哈本纳、莫伊索夫和克努森开创了体重管理的 ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Ozempic is a medication for Type 2 diabetes that helps control blood sugar, with the added side effect of weight loss.

High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

The study published in the Annals of Surgery found that bariatric surgery was linked to a 60% lower risk of kidney disease ...

Half a century of advancements in biomedical science paved the way for today’s powerful weight-loss drugs like Ozempic — so ...

Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...

The bold move has been accompanied by a full-page ad in the Wall Street Journal explaining its reasoning, and claiming that the prices of GLP-1 drugs for weight loss are five times too high and ...